GlassScriptPhysician profile
Robert J Mamlok
NPI 1255393252
$561.57
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $204 · 2021: $190.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $118.12 | 2020-2021 | |
| Pfizer INC. | $97.33 | 2019-2021 | |
| Kaleo, INC. | $93.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $75.03 | 2019-2021 | |
| Genzyme Corporation | $58.57 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.23 | 2020-2021 | |
| Horizon Therapeutics Plc | $26.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $24.82 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $21.77 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mamlok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.